Spectrum Pharmaceuticals (SPPI) Stock Price
Spectrum Pharmaceuticals Price
Revenue has compounded at 13.0% per year over the past 19 years to 10.11 M USD. Spectrum Pharmaceuticals's net margin stands at -772.2%, down from -109.8% several years earlier. The payout ratio is around 10% of earnings.
Spectrum Pharmaceuticals stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Spectrum Pharmaceuticals over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Spectrum Pharmaceuticals stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Spectrum Pharmaceuticals's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Spectrum Pharmaceuticals Price |
|---|
Spectrum Pharmaceuticals Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Spectrum Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 162.00 | 146.00 | 128.00 | 109.00 | 22.00 | – | – | 10.00 | 72.00 | 108.00 | 197.00 | 190.00 | 282.00 | 419.00 | 565.00 | 630.00 |
| -12.90 | -9.88 | -12.33 | -14.84 | -79.82 | – | – | – | 620.00 | 50.00 | 82.41 | -3.55 | 48.42 | 48.58 | 34.84 | 11.50 |
| 82.72 | 75.34 | 63.28 | 75.23 | 45.45 | – | – | 80.00 | 80.00 | 80.00 | 80.00 | 80.00 | 80.00 | 80.00 | 80.00 | 80.00 |
| 134.00 | 110.00 | 81.00 | 82.00 | 10.00 | 8.00 | 8.00 | 8.00 | 57.60 | 86.40 | 157.60 | 152.00 | 225.60 | 335.20 | 452.00 | 504.00 |
| -40.00 | -61.00 | -96.00 | -131.00 | -144.00 | -169.00 | -147.00 | -72.00 | -38.00 | 7.00 | 52.00 | 41.00 | 79.00 | 182.00 | 228.00 | 240.00 |
| -24.69 | -41.78 | -75.00 | -120.18 | -654.55 | – | – | -720.00 | -52.78 | 6.48 | 26.40 | 21.58 | 28.01 | 43.44 | 40.35 | 38.10 |
| -50.00 | -68.00 | -91.00 | -120.00 | -135.00 | -171.00 | -158.00 | -78.00 | -10.00 | 12.00 | 56.00 | -39.00 | – | – | – | – |
| 11.11 | 36.00 | 33.82 | 31.87 | 12.50 | 26.67 | -7.60 | -50.63 | -87.18 | -220.00 | 366.67 | -169.64 | – | – | – | – |
| 65.37 | 78.40 | 98.37 | 105.63 | 111.36 | 141.43 | 154.68 | 183.24 | 183.24 | 183.24 | 183.24 | 183.24 | 183.24 | 183.24 | 183.24 | 183.24 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Spectrum Pharmaceuticals generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Spectrum Pharmaceuticals retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Spectrum Pharmaceuticals's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Spectrum Pharmaceuticals has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Spectrum Pharmaceuticals's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Spectrum Pharmaceuticals stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Spectrum Pharmaceuticals Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Spectrum Pharmaceuticals business model & stock analysis
Spectrum Pharmaceuticals SWOT Analysis
Strengths
Spectrum Pharmaceuticals Inc has a strong portfolio of innovative oncology products, including FDA-approved drugs and investigational therapies. This diverse product pipeline provides the company with a competitive edge in the rapidly evolving cancer treatment market.
The company has a dedicated and experienced research and development team, constantly working towards developing new drugs and expanding their product offerings. This strong R&D capability positions Spectrum Pharmaceuticals Inc for continued growth and success.
Spectrum Pharmaceuticals Inc has also built strong partnerships with key industry players, such as academic institutions and biotechnology companies. These collaborations enable the company to leverage external expertise and resources, enhancing their ability to deliver innovative solutions to patients.
Weaknesses
One of the weaknesses of the company is its heavy reliance on a limited number of oncology products for revenue generation. Any setbacks or increased competition in the market for these specific products could significantly impact Spectrum Pharmaceuticals Inc's financial performance.
Moreover, the company may face challenges in effectively managing their research and development pipeline. The success rate of drug development is inherently low, and any failures or delays in the clinical trial process could hinder the company's ability to bring new therapies to market.
Spectrum Pharmaceuticals Inc's geographic presence is also somewhat limited, which may hinder their ability to capture market share beyond their current regions. Expanding into new markets and establishing a global presence will require additional investments and resources.
Opportunities
The growing global prevalence of cancer presents a significant opportunity for Spectrum Pharmaceuticals Inc to expand its market reach. By developing and commercializing effective oncology drugs, the company can tap into this increasing demand and capture a larger market share.
Furthermore, advancements in technology and personalized medicine offer the potential for targeted therapies, which can be a focus area for Spectrum Pharmaceuticals Inc. By leveraging these advancements, the company can develop tailored treatment options that provide enhanced patient outcomes and differentiate themselves from competitors.
Strategic collaborations and partnerships with academic institutions and biotechnology companies can also open doors for Spectrum Pharmaceuticals Inc to access novel technologies, intellectual property, and research capabilities. These partnerships can accelerate the innovation and development of new drugs, leading to potential breakthrough treatments.
Threats
Spectrum Pharmaceuticals Inc faces intense competition within the oncology market. Other pharmaceutical companies and biotech firms are also investing in oncology research and developing innovative therapies. This competitive landscape can pose challenges to Spectrum Pharmaceuticals Inc's market positioning and growth.
Additionally, regulatory hurdles and stringent approval processes can delay the commercialization of new drugs, impacting the company's ability to generate revenue. Compliance with evolving regulatory requirements and policies is crucial for Spectrum Pharmaceuticals Inc's success in bringing new products to market.
Economic factors and reimbursement policies in the healthcare industry can also influence the adoption and pricing of Spectrum Pharmaceuticals Inc's drugs. Changes in healthcare policies or downward pressure on drug prices could impact the company's profitability and market opportunities.
Spectrum Pharmaceuticals Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Spectrum Pharmaceuticals Segments
Spectrum Pharmaceuticals Revenue by Segment (1/3)
3 Years
5 Years
10 Years
Max
Details
Spectrum Pharmaceuticals Revenue by Segment (2/3)
3 Years
5 Years
10 Years
Max
Details
Spectrum Pharmaceuticals Revenue by Segment (3/3)
3 Years
5 Years
10 Years
Max
Details
Spectrum Pharmaceuticals Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Spectrum Pharmaceuticals Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Spectrum Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio
Spectrum Pharmaceuticals annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Spectrum Pharmaceuticals shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Spectrum Pharmaceuticals Dividend History
1 years of dividend payments
Spectrum Pharmaceuticals dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Spectrum Pharmaceuticals Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 5/26/2023 | Maintained | Neutral | – | |
| 5/25/2023 | Maintained | Neutral | – | |
| 5/15/2023 | Downgrade | BuyHold | 57 | |
| 5/14/2023 | Downgrade | BuyHold | 57 | |
| 4/26/2023 | Downgrade | Market OutperformPerform | – | |
| 4/26/2023 | Downgrade | BuyNeutral | – | |
| 4/25/2023 | Downgrade | Market OutperformPerform | – | |
| 4/25/2023 | Downgrade | BuyNeutral | – | |
| 2/6/2023 | Maintained | Market OutperformOutperform | – | |
| 2/3/2023 | Maintained | Neutral | 41 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Spectrum Pharmaceuticals Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/7/2024 | 0.01USD | - | 23.88 MUSD | - | 2024 Q1 |
| 3/20/2024 | 0.00USD | - | 22.29 MUSD | - | 2023 Q4 |
| 11/8/2023 | -0.05USD | - | 10.52 MUSD | - | 2023 Q3 |
| 8/9/2023 | -0.12USD | - | 7.02 MUSD | - | 2023 Q2 |
| 11/10/2022 | -0.15USD | - | 0.00USD | - | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Spectrum Pharmaceuticals stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Spectrum Pharmaceuticals shareholder structure
| % | Name |
|---|---|
9.27759% | |
4.58438% | |
1.94095% | |
1.85631% | |
0.89405% | |
0.82527% |
Spectrum Pharmaceuticals Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
19.10% | SEC ↗ | |
19.10% | SEC ↗ | |
10.20% | SEC ↗ | |
9.84% | SEC ↗ | |
9.84% | SEC ↗ | |
9.60% | SEC ↗ | |
8.70% | SEC ↗ | |
8.67% | SEC ↗ | |
8.50% | SEC ↗ | |
8.50% | SEC ↗ |
Spectrum Pharmaceuticals Executives and Management Board
10 members · avg. age 58 · 40 % women
Mr. Thomas Riga (46)
President, Chief Executive Officer, Director · since 2017
2.79 M USD
Management
Mr. Keith Mcgahan (47)
Executive Vice President, Chief Legal Officer, Corporate Secretary
Ms. Nora Brennan (53)
Chief Financial Officer, Director · since 2020
Board of Directors
Mr. William Ashton (71)
Non-Executive Independent Chairman of the Board
Dr. Jeffrey Vacirca (53)
Independent Director
Dr. Bernice Welles (68)
Independent Director
Dr. Dolatrai Vyas (77)
Independent Director
Mr. Seth Fischer (66)
Independent Director
Ms. Juhyun Lim (47)
Director
Spectrum Pharmaceuticals Supply Chain
Spectrum Pharmaceuticals Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.40 | 0.86 | 0.75 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.63 | 0.26 | — | ||
| 2 | 0.69 | -0.36 | -0.68 | ||
| 3 | 0.54 | 0.04 | 0.10 |
Frequently asked questions about Spectrum Pharmaceuticals
The business model of Spectrum Pharmaceuticals Inc revolves around the development, acquisition, and commercialization of innovative drug therapies for various oncology and hematology indications. As a leading biopharmaceutical company, Spectrum focuses on creating targeted and efficient treatments to address unmet medical needs in areas such as solid tumors and blood-related cancers. By leveraging its expertise in drug discovery and development, Spectrum aims to provide patients with effective and personalized treatment options. With a commitment to enhancing patient outcomes, Spectrum Pharmaceuticals Inc remains dedicated to advancing the field of oncology through its diverse portfolio of therapeutic offerings.
Spectrum Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Spectrum Pharmaceuticals Inc in the market are companies such as Pfizer Inc, Johnson & Johnson, Novartis AG, Roche Holding AG, and Bristol-Myers Squibb Company.
Spectrum Pharmaceuticals Inc, a leading biopharmaceutical company, has a rich history and background. Founded in 1987, the company focuses on developing and commercializing innovative therapies for challenging diseases. With a primary focus on hematology and oncology, Spectrum specializes in developing medicines that target unmet medical needs. Over the years, they have successfully launched several important drugs, including FOLOTYN® and KHAPZORY®, which have played a crucial role in improving patient outcomes. Their commitment to research, development, and commercialization has positioned Spectrum Pharmaceuticals as a trusted name in the biopharmaceutical industry. With a strong track record and dedication to advancing patient care, Spectrum continues to make significant contributions in the healthcare sector.
Spectrum Pharmaceuticals Inc has achieved several significant milestones. The company received FDA approval for its flagship product, FUSILEV, in 2011, enhancing its position in the oncology market. Spectrum also launched ZEVALIN, a radioimmunotherapy agent for treating relapsed or refractory non-Hodgkin's lymphoma, in partnership with Bayer Healthcare. Furthermore, the company expanded its product portfolio through acquisitions, including the purchase of Talon Therapeutics and Allos Therapeutics. Spectrum's dedication to innovation and strategic partnerships has enabled it to solidify its presence in the pharmaceutical industry and deliver value to its stakeholders.
Spectrum Pharmaceuticals Inc primarily operates in the United States.
Spectrum Pharmaceuticals Inc represents values of excellence, innovation, and patient-centricity. With a strong corporate philosophy focused on developing targeted therapies for challenging diseases, Spectrum is dedicated to improving the lives of patients through cutting-edge research and development. The company's commitment to fostering a culture of integrity, collaboration, and respect sets them apart in the pharmaceutical industry. Spectrum Pharmaceuticals Inc strives to create value for patients, shareholders, and healthcare providers by delivering high-quality and differentiated therapeutic options. With a customer-driven approach, Spectrum aims to positively impact healthcare outcomes while staying at the forefront of medical advancements.
10 analysts currently rate the Spectrum Pharmaceuticals stock: 0 recommend buying, 7 holding and 3 selling.
The Spectrum Pharmaceuticals share (SPPI) is listed on 5 stock exchanges, including: NASDAQ (SPPI), Frankfurt (NTR.F), München (NTR.MU), Düsseldorf (NTR.DU), SIX (Zürich) (NTR.SW).
Spectrum Pharmaceuticals Inc is a US-based publicly traded company that specializes in the development and marketing of cancer medications. The company is headquartered in Irvine, California and has been active in the industry since 1996. The company's business model includes providing cancer medications in various stages of clinical development, from preclinical research to market launch. With this approach, Spectrum Pharmaceuticals aims to meet the demand for innovative and effective cancer therapies. Spectrum Pharmaceuticals' product range includes several medications in different stages of development. One of the key products, already approved and commercially available in the US, is Belinostat, a histone deacetylase inhibitor (HDAC inhibitor) used for the treatment of peripheral T-cell lymphoma (PTCL). PTCL is a rare, aggressive cancer for which there is currently no specific treatment. Another product currently in clinical development is ROLONTIS, a pegylated granulocyte colony-stimulating factor (pegfilgrastim). ROLONTIS is intended for the treatment of neutropenia, a complication in cancer patients commonly caused by chemotherapy. Spectrum Pharmaceuticals also has other projects in its pipeline, including several in preclinical development. The company's goal is to offer a comprehensive range of cancer medications for a variety of cancer types. Another important aspect of Spectrum Pharmaceuticals' business model is collaboration with other companies and research institutions. The company has formed strategic partnerships with several biotech and pharmaceutical companies to conduct joint research and development projects. Through these partnerships, Spectrum Pharmaceuticals can expand its portfolio and share its resources and expertise with other companies. The company also pursues a growth strategy through mergers and acquisitions. In 2020, Spectrum Pharmaceuticals completed the acquisition of Hikma Pharmaceuticals' generic portfolio for US customers. The acquisition included 22 approvals for generic medications as well as a development team. Overall, Spectrum Pharmaceuticals focuses on a broad range of therapeutics to meet the demand for cancer medications. By collaborating with other companies and acquiring companies and product portfolios, the company aims to further expand its market position. Overall, Spectrum Pharmaceuticals' business model is focused on the development and marketing of cancer medications to meet the demand for innovative and effective cancer therapies. The company relies on a broad range of therapeutics and works closely with other companies and research institutions to expand its portfolio.
The revenue cannot currently be calculated for Spectrum Pharmaceuticals.
The profit cannot currently be calculated for Spectrum Pharmaceuticals.
The P/E ratio cannot be calculated for Spectrum Pharmaceuticals at the moment.
The P/S cannot be calculated for Spectrum Pharmaceuticals currently.
The Eulerpool Quality Score for Spectrum Pharmaceuticals is 2/10.
The ISIN of Spectrum Pharmaceuticals is US84763A1088. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Spectrum Pharmaceuticals is 164623. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Spectrum Pharmaceuticals is SPPI. The ticker symbol is used to trade Spectrum Pharmaceuticals shares on the stock exchange.
The current dividend yield of Spectrum Pharmaceuticals is - %.
Spectrum Pharmaceuticals is assigned to the 'Health' sector.
The dividends of Spectrum Pharmaceuticals are distributed in USD.
Spectrum Pharmaceuticals stock
Spectrum Pharmaceuticals Peer Group
Spectrum Pharmaceuticals Ticker
Spectrum Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Spectrum Pharmaceuticals
Our stock analysis for Spectrum Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Spectrum Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.